Plantronics New (PLT) Stock Value Declined While Profit Investment Management Has Boosted Holding; Sabby Management Decreased Holding in Esperion Therapeutics (ESPR) by $2.13 Million as Valuation Rose

Plantronics, Inc. (NYSE:PLT) Logo

Sabby Management Llc decreased its stake in Esperion Therapeutics Inc (ESPR) by 32.5% based on its latest 2018Q3 regulatory filing with the SEC. Sabby Management Llc sold 48,335 shares as the company’s stock rose 6.84% while stock markets declined. The hedge fund held 100,369 shares of the health care company at the end of 2018Q3, valued at $4.45 million, down from 148,704 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Esperion Therapeutics Inc for a number of months, seems to be less bullish one the $1.18B market cap company. The stock increased 3.98% or $1.68 during the last trading session, reaching $43.9. About 581,264 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 3.18% since January 11, 2018 and is downtrending. It has underperformed by 3.18% the S&P500. Some Historical ESPR News: 14/05/2018 – DEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. — ESPR; 04/05/2018 – Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference; 07/05/2018 – Kaskela Law LLC: Shareholder Class Action Filed Against Esperion Therapeutics, Inc. – ESPR; 07/03/2018 – Esperion: 12-week Study Met Its Primary Endpoint With LDL-C Lowering Totaling 28 %; 02/05/2018 – Esperion Therapeutics Cash and Cash Equivalents and Investment Securities Available-For-Sale Totaled $239.6M at March 31; 07/03/2018 – Esperion’s cholesterol drug succeeds in late-stage study; 14/05/2018 – Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm; 07/03/2018 – Esperion to Participate in Fireside Chat at March 2018 Investor Conferences; 22/05/2018 – Esperion Therapeutics Presenting at UBS Conference Tomorrow; 30/05/2018 – The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a

Profit Investment Management Llc increased its stake in Plantronics Inc New (PLT) by 28.25% based on its latest 2018Q3 regulatory filing with the SEC. Profit Investment Management Llc bought 11,498 shares as the company’s stock declined 37.52% with the market. The institutional investor held 52,199 shares of the public utilities company at the end of 2018Q3, valued at $3.15 million, up from 40,701 at the end of the previous reported quarter. Profit Investment Management Llc who had been investing in Plantronics Inc New for a number of months, seems to be bullish on the $1.42 billion market cap company. The stock decreased 0.92% or $0.33 during the last trading session, reaching $35.7. About 347,731 shares traded. Plantronics, Inc. (NYSE:PLT) has declined 23.74% since January 11, 2018 and is downtrending. It has underperformed by 23.74% the S&P500. Some Historical PLT News: 28/03/2018 – Plantronics To Acquire Polycom For $2 Billion; 01/05/2018 – Plantronics Sees 1Q Adj EPS 66c-Adj EPS 78c; 14/05/2018 – S&P REVISES PLANTRONICS, INC. OUTLOOK TO ‘NEGATIVE’ FROM CREDIT WATCH ‘NEGATIVE’; RATING ‘BB’; 24/04/2018 – Plantronics Backbeat Go 600 Wireless Headphones: Superior And Personalized Sound For Less Than $100; 30/03/2018 – Plantronics (PLT) Plantronics to Acquire Polycom Conference (Transcript); 28/03/2018 – MOODY’S PLACES PLANTRONICS RATINGS UNDER REVIEW AFTER PURCHASE; 01/05/2018 – PLANTRONICS INTRODUCES PLANTRONICS PARTNER PROGRAM; 28/03/2018 – PLANTRONICS INC – DEAL EXPECTED TO BE IMMEDIATELY ACCRETIVE TO NON-GAAP EPS; 28/03/2018 – Headsets maker Plantronics said it would buy Polycom in a deal valued at $2 billion; 21/03/2018 Plantronics Unveils Voyager 104: A Headset Designed For Trucking Professionals

Investors sentiment increased to 1.11 in Q3 2018. Its up 0.16, from 0.95 in 2018Q2. It increased, as 18 investors sold ESPR shares while 39 reduced holdings. 27 funds opened positions while 36 raised stakes. 24.60 million shares or 8.34% less from 26.84 million shares in 2018Q2 were reported. Nicholas Invest Prns LP holds 74,071 shares. Ameritas Investment Prtnrs Inc holds 1,993 shares or 0% of its portfolio. The New York-based Oz Mngmt LP has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). State Board Of Administration Of Florida Retirement System owns 10,371 shares for 0% of their portfolio. Aqr Capital Mgmt Ltd Liability stated it has 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Price T Rowe Md holds 303,036 shares or 0% of its portfolio. Geode Cap Limited Com owns 255,007 shares. Daiwa Grp owns 145 shares for 0% of their portfolio. 500 were reported by Parkside Fincl Bank. Bluefin Trading Ltd Limited Liability Company holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 347 shares. Morgan Stanley owns 71,700 shares. Raymond James And Associate holds 6,699 shares. Point72 Asset LP invested in 0.09% or 507,300 shares. Ellington Management Group Inc Limited Liability Corporation holds 4,700 shares. Moreover, Bamco New York has 0.02% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 100,000 shares.

Among 21 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 4 Sell and 6 Hold. Therefore 52% are positive. Esperion Therapeutics had 72 analyst reports since July 28, 2015 according to SRatingsIntel. RBC Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Friday, November 6. RBC Capital Markets has “Outperform” rating and $65 target. The stock has “Buy” rating by Northland Capital on Thursday, April 19. Citigroup upgraded the shares of ESPR in report on Tuesday, February 28 to “Buy” rating. Chardan Capital Markets maintained the shares of ESPR in report on Monday, August 31 with “Sell” rating. Barclays Capital maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, February 24. Barclays Capital has “Overweight” rating and $28 target. Citigroup downgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, November 14 to “Neutral” rating. Cowen & Co maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Tuesday, March 27 with “Buy” rating. Needham maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, October 18. Needham has “Buy” rating and $72.0 target. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Neutral” rating by Chardan Capital Markets on Tuesday, March 27. The rating was initiated by WallachBeth Capital on Monday, October 26 with “Buy”.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on February, 19. They expect $-1.33 earnings per share, up 7.64% or $0.11 from last year’s $-1.44 per share. After $-1.86 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -28.49% EPS growth.

Sabby Management Llc, which manages about $835.79 million and $781.50 million US Long portfolio, upped its stake in Zogenix Inc (Call) by 915 shares to 2,638 shares, valued at $13.08M in 2018Q3, according to the filing. It also increased its holding in Fibrogen Inc (Put) by 1,079 shares in the quarter, for a total of 1,444 shares, and has risen its stake in Marinus Pharmaceuticals Inc (Call).

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Nasdaq.com which released: “Esperion to Present at the 37th Annual JP Morgan Healthcare Conference – Nasdaq” on January 02, 2019, also Nasdaq.com with their article: “Noteworthy Friday Option Activity: ESPR, NTNX, SLDB – Nasdaq” published on January 04, 2019, Fool.com published: “Here’s Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today – The Motley Fool” on May 04, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Seekingalpha.com and their article: “Esperion Therapeutics halted pending news – Seeking Alpha” published on May 23, 2018 as well as Fool.com‘s news article titled: “All the Pre-JPM News Healthcare Investors Need to Know – The Motley Fool” with publication date: January 06, 2019.

Among 6 analysts covering Plantronics (NYSE:PLT), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Plantronics had 22 analyst reports since January 15, 2016 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Thursday, September 28. The stock has “Market Perform” rating by Raymond James on Wednesday, May 4. Sidoti upgraded the stock to “Buy” rating in Wednesday, August 8 report. The stock has “Buy” rating by Roth Capital on Wednesday, November 1. The stock of Plantronics, Inc. (NYSE:PLT) earned “Buy” rating by Northland Capital on Wednesday, January 31. The firm earned “Buy” rating on Monday, September 11 by Northland Capital. The stock of Plantronics, Inc. (NYSE:PLT) earned “Neutral” rating by Sidoti on Thursday, February 1. Northland Capital maintained the stock with “Buy” rating in Monday, July 24 report. The rating was upgraded by Sidoti to “Buy” on Tuesday, January 2. The rating was upgraded by JP Morgan to “Overweight” on Monday, January 18.

Investors sentiment increased to 1.3 in 2018 Q3. Its up 0.16, from 1.14 in 2018Q2. It increased, as 24 investors sold PLT shares while 59 reduced holdings. 47 funds opened positions while 61 raised stakes. 30.99 million shares or 3.60% more from 29.91 million shares in 2018Q2 were reported. Profund Limited holds 0.01% in Plantronics, Inc. (NYSE:PLT) or 5,969 shares. Martingale Asset Mngmt LP holds 0.02% of its portfolio in Plantronics, Inc. (NYSE:PLT) for 34,019 shares. Northern Tru reported 629,333 shares. 7,800 are held by New Mexico Educational Retirement Board. 4,840 were accumulated by Bnp Paribas Arbitrage Sa. Marshall Wace Llp holds 0.09% or 167,142 shares in its portfolio. Numerixs Investment owns 0.08% invested in Plantronics, Inc. (NYSE:PLT) for 7,300 shares. Balyasny Asset Mgmt Lc accumulated 23,984 shares or 0.01% of the stock. Citadel Advsrs Ltd Company owns 223,187 shares or 0.01% of their US portfolio. Blackrock has 3.99M shares. Mason Street Advsr Ltd Com owns 16,934 shares for 0.02% of their portfolio. D E Shaw has invested 0.01% of its portfolio in Plantronics, Inc. (NYSE:PLT). State Treasurer State Of Michigan invested in 12,200 shares or 0.01% of the stock. Gamco Invsts Et Al reported 40,000 shares stake. Laurion Capital Management Lp accumulated 0.01% or 10,580 shares.

More notable recent Plantronics, Inc. (NYSE:PLT) news were published by: Globenewswire.com which released: “Plantronics Announces Kathy Crusco as a New Board Member – GlobeNewswire” on August 13, 2018, also Globenewswire.com with their article: “Plantronics Adds Employee Engagement Expert and HR Innovator Anja Hamilton to Executive Team as Executive Vice President and Chief Human Resources Officer – GlobeNewswire” published on September 13, 2018, Globenewswire.com published: “Plantronics to Acquire Polycom for $2 billion NYSE:PLT – GlobeNewswire” on March 28, 2018. More interesting news about Plantronics, Inc. (NYSE:PLT) were released by: Globenewswire.com and their article: “Plantronics Opens the Door for ITSP Partners with New VVX x50 Series Obi Edition Phones – GlobeNewswire” published on November 15, 2018 as well as Globenewswire.com‘s news article titled: “Plantronics Unveils Voyager 104: A Headset Designed For Trucking Professionals – GlobeNewswire” with publication date: March 21, 2018.

Since September 5, 2018, it had 0 insider purchases, and 5 insider sales for $412,919 activity. 31 shares were sold by SARKAR SHANTANU, worth $2,039. The insider BURTON JOSEPH B sold $281,018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart